Caribou Biosciences Stock Fundamentals
| CRBU Stock | USD 1.01 0.02 2.02% |
Caribou Biosciences fundamentals help investors to digest information that contributes to Caribou Biosciences' financial success or failures. It also enables traders to predict the movement of Caribou Stock. The fundamental analysis module provides a way to measure Caribou Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Caribou Biosciences stock.
Caribou |
Caribou Biosciences Company Current Valuation Analysis
Caribou Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Caribou Biosciences Current Valuation | (91.39 M) |
Most of Caribou Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Caribou Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Caribou Biosciences has a Current Valuation of (91.39 Million). This is 100.64% lower than that of the Biotechnology sector and 101.97% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.55% higher than that of the company.
Caribou Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Caribou Biosciences's current stock value. Our valuation model uses many indicators to compare Caribou Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Caribou Biosciences competition to find correlations between indicators driving Caribou Biosciences's intrinsic value. More Info.Caribou Biosciences is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Caribou Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Caribou Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Caribou Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Caribou Biosciences could also be used in its relative valuation, which is a method of valuing Caribou Biosciences by comparing valuation metrics of similar companies.Caribou Biosciences is currently under evaluation in current valuation category among its peers.
Caribou Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (18.43) % | ||||
| Current Valuation | (91.39 M) | ||||
| Shares Outstanding | 93 M | ||||
| Shares Owned By Insiders | 10.08 % | ||||
| Shares Owned By Institutions | 61.60 % | ||||
| Number Of Shares Shorted | 8.91 M | ||||
| Price To Book | 0.36 X | ||||
| Price To Sales | 9.17 X | ||||
| Revenue | 9.99 M | ||||
| Gross Profit | (119.56 M) | ||||
| EBITDA | (166.62 M) | ||||
| Net Income | (149.1 M) | ||||
| Cash And Equivalents | 339.92 M | ||||
| Cash Per Share | 5.59 X | ||||
| Total Debt | 26.49 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.23 X | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | (138.2 M) | ||||
| Short Ratio | 7.92 X | ||||
| Earnings Per Share | (1.65) X | ||||
| Price To Earnings To Growth | 0.50 X | ||||
| Target Price | 14.29 | ||||
| Number Of Employees | 147 | ||||
| Beta | 2.34 | ||||
| Market Capitalization | 91.66 M | ||||
| Total Asset | 313.31 M | ||||
| Retained Earnings | (448.39 M) | ||||
| Working Capital | 188.73 M | ||||
| Net Asset | 313.31 M |
About Caribou Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Caribou Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caribou Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caribou Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.